Program

The previous International Symposium was focussed on regulatory autoantibodies:

  • Contribution of RABs to the pathogenesis of diseases and disease manifestations
  • Diagnostic methodologies and their associated challenges.
  • The potential of anti-GPCR antibodies as biomarkers for diseases and therapeutic interventions.

What is our Symposium about

  • We promote interdisciplinary conversations and strengthen research network.
  • We identify new pathogenic targets, biomarkers, and intricate signallingpathways to provide a comprehensive perspective on disease pathogenesis.
  • We propose and pioneer new therapeutic strategies.
9:00 a.m. Desk opening
10:00 a.m. Welcome address:
Thomas Münte, Universität zu Lübeck
10:15 a.m. Current concepts in the development of autoimmune diseases
Yehuda Shoenfeld

5th anniversary RAB: Challenges in GPCR ab research: from biomarker research to precision medicine
Gabriela Riemekasten
11:25 a.m. Coffee break
11:55 a.m. Session: Regulation of Chronic Inflammation:
Chair: Guido Moll

Identification of novel functional autoantibodies associated with systemic sclerosis
Xinhua Yu & Jacqueline Wax

Anti-GPCR ab correlations: lessons from systemic sclerosis and its vascular and fibrotic complications
Susanne Schinke

Age-associated dynamics of the autoantibodyome: a way to stay old and healthy
Otavio Cabral Marques
12:55 p.m. Lunch and Posterwalk
14:05 p.m. Session: RABS in Neuroimmunology:
Chair: Gabriela Riemekasten

New insights of RABs in myalgic encephalomyelitis / chronic fatigue syndrom ME/CFS and post Covid syndrome.
Carmen Scheibenbogen

EBV-reacitve antibodies crossreact with GPCR and other autoantigens in ME/CFS: from immunoadsorption to B cell depletion
Franziska Sotzny

Autoimmune Neuroinflammation – Pathogenic and Regulatory Autoantibodies
Friedemann Paul

Phenotypes of autonomic dysfunction in post-COVID syndrome can be related to signatures of regulatory autoantibodies
Frank C. Mooren

Emerging potential of CAR-T Cell therapy in Neurology
Aiden Haghikia
15:45 p.m. Coffee Break and Poster Session
16:15 p.m.

Session: Inside Antibody Induced Cellular Functions
Chair: Miroslav Banasik

GPCR abs and ligand induced receptor activation: measuring the interplay between ligand and abs
Dmitry Veprintsev

Angiotensin II type 1 receptor ABs induce endothelial activation and dysfunction in systemic sclerosis
Reza Akbarzadeh & Carolin Schmidt

RABs targeting glycocalyx in systemic sclerosis
Maj Jäpel

Unexpected impacts of IL-6 on development of pulmonary occlusive vasculopathy in an AT1R-induced mouse model of systemic sclerosis
Afsaneh Mehrpouyan

17:25 p.m. Closing
9:00 a.m. Desk opening
10:00 a.m. Session: RABs as Precision Biomarker in Immunity, Cancer and Transplantation
Chair: Torsten Witte

Autoantibodies in transplantation
Guido Moll

Regulatory autoantibodies targeting GPCRs in transplant rejection and glomerulonephritis
Miroslav Banasik

Endothelin-1 directed RABs in systemic sclerosis
Pinchao Wang

Vasculitis pathogenesis driven by regulatory antibodies: insights from AAV, GCA, and EGPA
Sebastian Klapa
11:40 a.m. Coffee break
12:10 a.m. Session: Insight Beyond anti-GPCR as Biomarker:
Chair: Carmen Scheibenbogen

PAR2 abs and other GPCR abs as predictors in Ischemic Stroke
Matthias Endres

Antibodies against muscarinic receptors in Sjögren‘s syndrome
Torsten Witte

Calcium-sensing-receptor (CASR)-specific autoantibodies
Michael Adu-Gyamfi

Gut dysmotility through GPCR abs in Systemic Sclerosis
Konstantinos Fourlakis
13:30p.m. Lunch and Poster Session
14:30 p.m. Session: Complexity of RABs and Vesicles
Chair: Franziska Sotzny

RABs and exosomes in rheumatoid arthritis: from tissue priming to tissue damage
Markus Hoffmann

Axis of trouble: AT1R, AT1R-abs and AT1R-EVs in scleroderma-associated interstitial lung disease
Alexander Hackel

Revised insights into exosome characteristics in systemic sclerosis
Maike Winziers
15:25 p.m. Coffee Break
15:55 p.m. Session: Therapeutic Targeting
Chair: Yehuda Shoenfeld

Autoantibody targeting in post Covid and ME/CFS: from immunoadsorption to B cell depletion.
Carmen Scheibenbogen

RABs in chronic inflammation and as predictors of therapy in psoriatic arthritis and inflammatory bowel disease
Hanna Graßhoff
16:45 p.m. Closing Remarks
Gabriela Riemekasten